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Impaired activity of the lysosomal enzyme glucocerebrosidase (GCR) results in the inheritedmetabolic disorder known as Gaucher
disease. Current treatment consists of enzyme replacement therapy by administration of exogenous GCR. Although eﬀective, it
is exceptionally expensive, and patients worldwide have a limited access to this medicine. In Brazil, the public healthcare system
provides the drug free of charge for all Gaucher’s patients, which reaches the order of $ 84million per year. However, the production
of GCR by public institutions in Brazil would reduce significantly the therapy costs. Here, we describe a robust protocol for the
generation of a cell line producing recombinant human GCR. The protein was expressed in CHO-DXB11 (dhfr−) cells after stable
transfection and gene amplification with methotrexate. As expected, glycosylated GCR was detected by immunoblotting assay
both as cell-associated (∼64 and 59 kDa) and secreted (63–69 kDa) form. Analysis of subclones allowed the selection of stable
CHO cells producing a secreted functional enzyme, with a calculated productivity of 5.14 pg/cell/day for the highest producer.
Although being laborious, traditional methods of screening high-producing recombinant cells may represent a valuable alternative
to generate expensive biopharmaceuticals in countries with limited resources.
1. Introduction
Glucocerebrosidase (GCR; EC 3.2.1.45) is a membrane-
associated lysosomal enzyme [1] responsible for the hydrol-
ysis of glucocerebroside to glucose and ceramide [2, 3].
Deficiency in the GCR activity results in Gaucher disease, the
most common lysosomal storage disorder [4] characterized
by an accumulation of the glycolipid in the monocyte-
macrophage system [5, 6], mainly in liver, spleen and
bone marrow. Gaucher disease is an autosomal recessive
disorder [7], caused by more than 300 mutations in the
GCR gene [5, 8], which results in a highly variable clinical
presentation. According to the symptoms, Gaucher disease
is historically classified into types I, II, and III [4, 6].
Type I (nonneuronopathic) is the most prevalent form [9],
usually treated by enzyme replacement therapy (ERT) [10]
via intravenous infusions of recombinant GCR produced in
Chinese hamster ovary (CHO) cells [11]. ERT has proven to
be safe and eﬀective [8], reversing most symptoms of the
disease in more than 4,500 patients worldwide [12]. This
therapy was first introduced in 1991, using human placental-
derived GCR (aglucerase, Ceredase) that was then replaced
in 1994 by the recombinant form (imiglucerase, Cerezyme)
[5, 12, 13], both manufactured by Genzyme Corporation
(Cambridge, MA, USA), which was latterly acquired by
Sanofi-Aventis (Montpellier, France). Currently, two new
recombinant GCRs, regarded as biosimilar (or follow-on)
preparations of imiglucerase [14], have received market
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approval [15, 16]: a gene-activated GCR (velaglucerase
alfa, VPRIV, Shire Human Genetic Therapies, Cambridge,
MA, USA) produced in a human fibroblast cell line [17–
19] and a plant-derived human GCR (taliglucerase alfa,
Elelyso, Protalix Biotherapeutics, Carmiel, Israel) [20, 21].
Recently, a viral contamination occurred in the Genzyme’s
bioreactor resulting in a global supply shortage of Cerezyme.
As a consequence, both enzymes velaglucerase alfa and
taliglucerase alfa had an accelerated market entry [22]. There
is a great expectation that these and possibly other GCR
formulations emerging in the near future could lead to
a reduction in the price of the drug, which is extremely
expensive [8] and hampers access to treatment [2, 14],
especially in countries with limited resources [23–25]. Here,
we propose the cloning and expression of human GCR in
CHO cells, in order to obtain high-expressing clones suitable
for future GCR production at a lower cost by Institute
Butantan (Sa˜o Paulo, Brazil). The Institute Butantan has
the public mission of producing sera, vaccines, and bio-
pharmaceuticals at reduced costs for the Brazilian public
healthcare system. The GCR cDNA was inserted into the
pED dicistronic expression vector [26], and the recombinant
protein was expressed in CHO-DXB11 cells, an auxotrophic
line deficient in dihydrofolate reductase (DHFR) activity
[27]. This is a well-characterized expression system [28, 29],
commonly used in the biopharmaceutical industry for the
production of glycoproteins [30, 31]. Cells were submitted
to gene amplification with increasing methotrexate (MTX),
a competitive inhibitor of DHFR, and clones were selected
by traditional methods to screen high producers since
current high-throughput techniques are not available to
most undeveloped or emerging countries. The properly
glycosylated GCR was detected in the culture supernatants
and cellular extracts. Subcloning of the best producer clone
followed by long-term culture in the MTX-free medium
allowed the selection of stable CHO cell lines producing a
functional enzyme. In addition to a successful protocol for
the generation of stable cells producing recombinant human
GCR, this study shows that traditional screening methods
to search for high-producing cell lines for recombinant
proteins can be a useful alternative for the production of
biopharmaceuticals in emerging countries.
2. Materials and Methods
2.1. Recombinant DNA Procedures. Human GCR cDNA was
obtained by purification of total RNA from ECV 304 cells
(ATCC CRL 1998), followed by cDNA synthesis through
RT-PCR (results not shown). The 1,565 bp cDNA encoding
human GCR with its own signal peptide was amplified by
PCR using the forward primer (5′ TCT AGA CCA TGG
CTG GCA GCC TCA CA 3′) containing a XbaI restriction
site and the Kozak sequence (sequence in bold), and the
reverse primer (5′ GAA TTC TCA CTG GCG ATG CCA
CAG 3′) containing an EcoRI restriction site. PCR was
performed using Pfx DNA polymerase (Invitrogen), 0.2mM
of each deoxynucleoside triphosphate and 20 pmol of each
primer. PCR amplification conditions were as follows: 94◦C,
5min; 30 cycles of 94◦C, 1min; 52◦C, 45 s; 68◦C, 3min;
a single step of 68◦C, 7min for final extension. PCR
products were cloned into the pGEM-T vector (Promega).
DH5α E. coli competent cells were transformed with the
ligation product for propagation and amplification of the
recombinant DNA. Positive clones were confirmed by DNA
sequencing using an automated DNA sequencer (ABI 3100)
based on the dideoxytermination method [32]. The GCR
cDNA was mutated to produce an enzyme with His in
place of Arg at position 495 (procedures not shown)
(Figure 1). The resulted plasmid pGEM-T-GCR was digested
and the insert was subcloned into the XbaI and EcoRI
sites of the pED expression vector [26], kindly provided
by Dr. R. J. Kaufman (Howard Hughes Medical Institute,
University of Michigan Medical Center), which provides
high-expression levels of heterologous proteins in mam-
malian cells based on a dicistronic expression system. The
pED vector carriers the encephalomyocarditis virus leader
sequence, a putative internal ribossomal entry site, inserted
upstream of the selectable and amplifiable gene marker dhfr
(Figure 1).
2.2. Cell Culture, Stable Transfection and Gene Amplification.
Cells of the lineage CHO-DXB11 (dhfr−) [27] kindly
provided by Dr. L. A. Chasin (Department of Biological
Sciences, Columbia University), were maintained in Min-
imum Essential Medium Alfa Medium (α-MEM; Invit-
rogen) supplemented with 2mM L-glutamine, antibiotics
(100U/mL penicillin, 100 μg/mL streptomycin, 0.25 μg/mL
amphotericin B; Invitrogen) and 10% fetal bovine serum
(FBS; Cultilab) (nonselective medium). Transfection of the
plasmid pED-GCR (20 μg) was carried out in 100mm
tissue culture plates containing 106 cells by the calcium
phosphate precipitation method [33]. The medium was
replaced 48 h after transfection by α-MEM without nucleo-
sides and supplemented with 10% dialyzed FBS (Invitrogen),
antibiotics and L-glutamine (selective medium). After 2
weeks, 48 DHFR-positive clones (named as C 1 to C 48)
were transferred into 12-well tissue culture plates using
plastic inoculating loops and submitted to gene amplification
with increasing MTX (Sigma) in the selective medium at
concentrations of 0, 20, 50, 150, 350, 700, and 1200 nM.
Cells were fed with fresh medium every 2-3 days and
were passaged upon reaching confluence by trypsinization.
In each selection step, cells were cultivated for at least
15 days before the MTX concentration was increased.
To generate conditioned media and cell lysates for GCR
expression analysis, cell clones were seeded into 6-well tissue
culture plates containing selective medium and MTX. When
semiconfluence was reached, cells were washed 3 times with
PBS and the culture medium was replaced by selective
medium lacking FBS. After incubation for 24 h, both the
culture medium (conditioned medium) and the cells were
collected, centrifuged at 300×g for 10min, and stored at
−80◦C until use. Cell concentration was determined for each
well with a Neubauer hemocytometer. For some analyses,
cell culture supernatants were precipitated with 10% (v/v)
trichloroacetic acid (TCA) and washed with cold acetone.
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Figure 1: Strategy of cloning of GCR cDNA in the mammalian expression vector pED. (a) Map of dicistronic vector pED, a pUC 18
derivative, containing the simian virus 40 (SV40) origin of replication and enhancer element, the adenovirus major late promoter (AdMLP),
the tripartite leader from adenovirus late mRNA (AdTPL), a hybrid intron composed of the 5′ splice site from the first leader of adenovirus
major late mRNAs and a 3′ splice site from an immunoglobulin gene (IVS), a multiple cloning site (SMC), the 5′ untranslated leader
from encephalomyocarditis (EMC-L) virus, a murine DHFR-coding region, the simian virus 40 late polyadenylation signal (SV40-pA), and
ampicillin resistance gene for propagation and selection in E. coli (AmpR) [26]. GCR cDNA was cloned into XbaI and EcoRI sites. (b) Amino
acid sequence of cloned GCR cDNA. The signal peptide of 19 amino acids is underlined. Potential carbohydrate binding asparagine residues
are shown by diamonds. The arginine at position 495 was replaced by histidine (mutation R495H) (boxed).
All cell cultures were carried out at 37◦C in a humidified
incubator with 5% CO2.
2.3. Single-Cell Subcloning Procedures. To isolate a cell line
with the highest GCR productivity, cells from the best clone
obtained at 700 nM MTX were subcloned by seeding 50,
100, and 200 cells into 3 separate 100mm tissue culture
plates and maintained in selective medium supplemented
with MTX. After 15 days, 24 single-cell subclones (named as
SC 12.1 to SC 12.24) were randomly selected, transferred to
12-well tissue-culture plates using plastic inoculating loops
and expanded in the same medium for storage.
2.4. Clonal Stability Studies. The highest producer clone
and the isolated subclones were cultured into 12-well tissue
culture plates for 45 days in the absence of MTX selection
pressure in nonselective medium. Cells were seeded into 6-
well tissue culture plates to obtain conditioned media, as
previously described. Samples were collected on days 15, 30,
and 45 of the culture, and analyzed for secreted GCR. Cell
concentration was determined by counting each well after
collection of the supernatant.
2.5. Western Blotting Analysis. CHO-DXB11 cell super-
natants (conditioned media) in 1-fold SDS-PAGE sample
buﬀer and CHO cell pellets lysed in 2-fold SDS-PAGE
sample buﬀer, containing 8M urea, 1.5mM EDTA and a
protease inhibitor cocktail (Sigma) were fractionated on a
10% SDS-PAGE and electrotransferred to nitrocellulose or
PVDF membranes (GE Healthcare). The membranes were
blocked with 5% (w/v) nonfat dried milk in 0.1% (v/v)
Tween 20, 150mMNaCl, and 20mM Tris-HCl pH 8.0 (TBS-
T) for 16 h. Membranes were washed three times for 10min
with TBS-T, and further incubated with a 1 : 4,000 dilution
of the murine anti-human GCR polyclonal antibodies [34],
in 1% (w/v) bovine serum albumin (BSA)/TBS-T, for 1.5 h.
The membranes were washed three times with TBS-T and
incubated for 1 h with a proper dilution of anti-mouse
IgG peroxidase conjugate (Sigma) in TBS-T, washed, and
revealed with ECL or ECL Plus detection reagent (GE
Healthcare), following manufacturer’s instructions.
2.6. Enzymatic Activity Assay. Hydrolytic activity of secreted
GCR was determined fluorometrically with synthetic sub-
strate 4-methylumbelliferyl-β-D-glucopyranoside (4-MUG;
Sigma). The enzymatic reactions were performed in 0.2mL
of 0.2M citrate phosphate buﬀer pH 5.5, containing 0.15%
(v/v) Triton X-100 (Sigma), 0.125% (w/v) sodium tauro-
cholate (Sigma), 5mM 4-MUG, and conditioned media
(collected as described above). After incubation for 1 h at
37◦C, the reactions were stopped by adding 1mL of 0.1M
glycine, 0.1M NaOH pH 10.3. The product of enzymatic
reactions 4-methylumbelliferone (4-MU)wasmeasured with
a spectrometer SLM-AMINCO Bowman Series II (Spec-
tronic Instruments) excitation wavelength 365 nm, emission
wavelength 445 nm. A standard curve was constructed
using well-known concentrations of commercial enzyme
Cerezyme and specific activity data (40U/mg) presented
by the manufacturer. Total protein concentrations were
determined by absorbance at 205 nm [35].
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2.7. GCR Quantification. Quantification of recombinant
human GCR secreted from CHO-DXB11 cell subclones
was estimated by a standard curve containing well-known
concentrations of nonglycosylated recombinant GCR puri-
fied from E. coli [34] on a 10% SDS-PAGE, followed by
western blotting and densitometry analysis. Conditioned
media used for GCR quantification were collected as previ-
ously described. Densitometry analysis was performed using
software from Eagle Eye still video system (Stratagene).
2.8. Endoglycosidase Digestion. Endo H and PNGase F diges-
tion of recombinant GCR were performed in conditioned
medium of the best producer subclone previously precipi-
tated with 10% (v/v) TCA and washed with cold acetone.
Samples were heated for 10min at 100◦C in glycoprotein
denaturing buﬀer, and reactions were performed according
to the manufacturer’s instructions (New England Biolabs).
After incubation at 37◦C for 16 h, reaction products were
subjected to 10% SDS-PAGE followed by western blotting
analysis, as described above.
3. Results
3.1. GCR Expression in CHO-DXB11 Cells. The human GCR
cDNA containing its signal peptide sequence (1,565 bp)
and the mutation R495H was cloned into the pED vector
(Figure 1) for stable expression of GCR in CHO-DXB11
cells, with the aim of obtaining high-producing clones.
Transfection eﬃciency using calcium phosphate was about
0,1%. Transfected clones were treated with increasing MTX
concentrations to amplify the copy number of integrated
cDNA. After the third round of amplification with 150 nM
MTX, protein bands corresponding to glycosylated recombi-
nant GCR were detected by western blotting analysis, using
an anti-human GCR polyclonal antibody (Figure 2). Two
to three GCR bands of 63–69 kDa were observed in the
conditioned media (Figure 2(a)), while bands around 64 and
59 kDa were detected in cell lysates (Figure 2(b)). A 56 kDa
band was detected (Figures 2(a) and 2(b)) corresponding to
nonglycosylated recombinant GCR purified from E. coli [34]
(positive control).
The amplification process was followed using increasing
concentrations ofMTX up to 700 nM in the culture medium.
Utilization of MTX at higher concentration (1200 nM) was
discontinued because it induced a high rate of cell death.
At each increase step of MTX concentration, conditioned
media were collected to evaluate the GCR expression by
the cells. The western blotting analysis, performed with the
anti-human GCR polyclonal antibody, showed that GCR
expression levels were higher with increasing MTX concen-
tration, which was evident in the last step with 700 nM
MTX in the culture medium (Figure 3). The nonglycosylated
recombinant GCR of 56 kDa purified from E. coliwas used as
positive control. These results suggested that 700 nM was the
highest concentration of MTX suitable for the amplification
of the cDNA and consequently the generation of high-
producer clones for GCR. With this purpose, clones selected
at 700 nM MTX were evaluated for GCR expression by
western blotting analysis, and the clone 12 was chosen as the
best expressing clone for GCR enzyme (data not shown).
3.2. Subcloning and Cell Culture in MTX-Free Medium. In
order to evaluate the clonal stability for GCR expression,
the high-producer clone (clone 12) was cultivated for 45
days in the absence of MTX selective pressure, and samples
of conditioned medium were collected on days 15, 30, and
45. The western blotting assay showed a decreasing in the
GCR expression over time (Figure 4(a)). After 45 days,
the expression level of GCR by clone 12 was similar to
that of nontransfected CHO-DXB11 cells (negative control),
indicating absence of the recombinant protein expression.
Since this analysis was carried out using a pool of cells, we
hypothesized that most of the cells were unstable and only a
few stably GCR expressing cells were present in the culture.
To identify stable high-producer cells from the amplified
pool of cells derived from clone 12, a single-cell subcloning
process was performed. The western blotting analysis of the
conditioned culture medium of subclones cultivated for 45
days in the absence of MTX showed evident bands around
66 kDa corresponding to recombinant GCR in 5 subclones
analyzed (Figure 4(b)). The GCR expression level observed
for these subclones was similar to that detected for the
clone 12 maintained with 700 nMMTX, and used as positive
control. For 13 additional subclones analyzed in the absence
of MTX, the GCR expression was not detected (data not
shown).
3.3. Hydrolytic Activity of Recombinant GCR. The hydrolytic
activity of secreted recombinant GCR was evaluated using
the synthetic substrate 4-MUG for the 5 stable producer
subclones identified in the western blotting analysis (Fig-
ure 4(b)). The presence of a functional GCR was observed
for all subclones analyzed (Figure 5). Specific activities were
calculated based on a standard curve containing well-known
units of Cerezyme. GCR produced by subclones showed
similar specific activities to commercial enzyme, taking into
account that the protein had not been purified from the
culture medium. The highest activity for GCR was detected
in subclone 12.9 (28.54± 2.75μmol 4-MU/min/mg).
3.4. GCR Expression Levels. Recombinant GCR secreted
from the best CHO-DXB11 cell subclones was quantified
by western blotting and densitometry analysis, based on
a standard curve of nonglycosylated recombinant GCR
purified from E. coli. As observed in Table 1, subclone 12.9
showed the highest specific productivity of recombinant
GCR (5.14 pg/cell/day), followed by subclones 12.19 and
12.8 (3.22 and 1.84 pg/cell/day, resp.). These results are in
agreement with the enzymatic activity assay that showed the
same order of potency to hydrolyze the synthetic substrate
4-MUG by these subclones. The subclone 12.9 was then
selected as the best producer of recombinant GCR in secreted
form.
3.5. Glycosylation Analyses of Recombinant GCR. Recom-
binant GCR secreted from the highest producer subclone
Journal of Biomedicine and Biotechnology 5
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Figure 2: Western blotting analysis of the expression of recombinant human GCR in stably transfected CHO-DXB11 cells, after the third
round of amplification with 150 nMMTX. (a) Conditionedmedia of 5 selected clones (C 12, C 20, C 22, C 37, and C 45). (b) Cellular extracts
from the selected clones and the corresponding membrane stained with Ponceau S after proteins transfer. The total protein from conditioned
media was previously concentrated by precipitation with 10% TCA. Nonglycosylated recombinant human GCR of 56 kDa purified from E.
coli was used as positive control. Conditioned medium and cellular extract of nontransfected CHO-DXB11 cells were the negative control.
Glycosylated recombinant GCR bands of 59–69 kDa are indicated by the arrows. The volume of sample applied to the gel corresponded to
the supernatant (a) or extract (b) of 150,000 cells.
Table 1: Expression levels of recombinant GCR secreted from the
best CHO-DXB11 cell subclones.
Subclone Productivity (pg/cell/day)∗
12.8 1.84
12.9 5.14
12.19 3.22
∗
The productivities were calculated by comparing the GCR bands of
subclones with a standard curve of non-glycosylated recombinant GCR
purified from E. coli, in a western blotting assay followed by densitometric
analysis. The experiment was conducted in triplicate. The volume of
conditioned medium applied to the gel corresponded to the supernatant of
70,000 cells.
(SC 12.9) was characterized by digestion with Endo H and
PNGase F. The western blotting (Figure 6(a)) showed a shift
in the molecular mass of the protein from 66–69 kDa to
56 kDa after PNGase F digestion, which is in agreement
with the expected size for nonglycosylated GCR. A 56 kDa
band was also observed for recombinant GCR purified from
E. coli (positive control). In the treatment with Endo H,
GCR was partially resistant. A decrease of ∼3 kDa in the
69 kDa protein band corresponding to the loss of N-linked
high-mannose-type oligosaccharide was observed, with the
probable retention of complex-type oligosaccharides termi-
nating in galactose or sialic acid, which are not digested
by Endo H. No recombinant GCR bands were detected
in the culture medium of nontransfected CHO-DXB11
cells (negative control). Analysis using purified commercial
enzyme (Cerezyme) of 60 kDa containing remodeled glycans
(Figure 6(b)) confirmed the glycosylation status of GCR
produced by CHO cells with a pattern of two bands
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Figure 3: Recombinant GCR expression in conditioned media of 3 CHO-DXB11 cell clones selected throughout the stages of amplification,
by western blotting analysis. (a) Clone 12, (b) clone 22, and (c) clone 37. Nonglycosylated recombinant GCR of 56 kDa purified from
E. coli was the positive control. Glycosylated recombinant GCR is indicated by arrows. The volume of culture medium applied to the gel
corresponded to the supernatant of 5,000 cells.
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Figure 4: Expression of secreted GCR from transfected CHO-DXB11 cells selected at 700 nM MTX and cultivated for 45 days in MTX-
free medium, by western blotting analysis. (a) Conditioned media of the high-producer clone (C 12) collected on days 15, 30, and 45.
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Figure 5: Enzymatic activity of recombinant GCR secreted from
CHO-DXB11 cell subclones (SC). The reactions were carried out
with the synthetic fluorogenic substrate 4-MUG. The product of
enzymatic reactions 4-MU was measured at wavelength of 445 nm
after excitation at 365 nm. A standard curve (units per fluorescence)
was constructed using specific activity data of Cerezyme. Results
are specific activities obtained for subclones relative to Cerezyme,
presented as means ± SEM, measured in triplicate. The volume of
conditioned medium used in this assay corresponded to the super-
natant of 70,000 cells.
(66 and 69 kDa), as observed by endoglycosidase treatment
and described elsewhere [36, 37].
4. Discussion
Although ERT has become the standard of care for type I
Gaucher disease [8, 38], its extremely high cost prevents it
from being available to many patients in several countries
[14, 23–25]. In Brazil, the drug is imported and provided
by the public healthcare system free of charge and the
cost for just 610 Gaucher’s patients reaches the order of
$ 84 million per year (Department of Science, Technology
and Strategic Inputs, personal communication, 2010), a value
not comparable with the expenses to treat other priority
diseases. However, the high cost of treatment could be
reduced with the production of GCR by public institutions.
GCR is a glycoprotein of 497 amino acids with four of
the five putative N-glycosylation sites usually occupied [39].
The glycosylation process was proven to be essential to
produce a catalytically active enzyme [39, 40]. For this
reason, GCR has been produced in eukaryotic cells that have
the machinery required to perform the posttranslational
modifications [41–43]: Genzyme has used CHO-DG44 cells
to produce imiglucerase [44], based on the dhfr amplifiable
gene marker, while Shire and Protalix have developed a gene-
activated expression system in a human fibroblast cell line
and a plant (carrot) cell-based expression system to produce
velaglucerase alfa and taliglucerase alfa [19, 21], respectively.
In contrast to velaglucerase that have an amino acid sequence
identical to that of the natural enzyme, imiglucerase, and
taliglucerase contain a mutation at position 495 (an Arg
to His substitution). In addition, taliglucerase sequence is
modified at the N- and C-termini to add short tags of 2
and 7 amino acids, respectively. In this work, we describe the
cloning of GCR cDNA containing the mutation R495H and
the protein expression in CHO-DXB11, a cell line deficient
in the DHFR synthesis, similar to CHO-DG44 cells.
The GCR cDNA was cloned into the pED dicistronic
expression vector, which is commonly used to obtain high-
expression levels of heterologous proteins in mammalian
cells [45–47], and positive clones were isolated and amplified
with increasing MTX concentration up to 700 nM MTX.
Probably due to the inability of the transfected cells to
further amplify the dhfr gene [28], higher concentration
of MTX (1200 nM) caused cell death. MTX selection of
amplificants has been considered a major bottleneck in
the production of biopharmaceuticals because many rounds
are required to obtain cells with high-gene copy numbers
[28, 48]. Currently, high-throughput methods to screen
high-producer cells have been developed [48, 49]; including
automated systems such as colony picking and the Cello
systems [50]. However, many of these techniques are very
expensive and nonaccessible to most undeveloped or emerg-
ing countries. In this regard, although time consuming
and labor intensive, traditional methods of screening still
represent an alternative for the production of recombinant
glycoproteins at lower cost. Some significant problems of
using traditional techniques are the relative low number of
clones that can be characterized, and the need of downstream
analysis of the product levels, since protein secretion cannot
be measured on an individual cell basis [50].
Using traditional methods of screening for recombi-
nant production clones, we demonstrated by immunoassays
the expression of recombinant GCR either cell-associated
(∼64 and 59 kDa) or secreted into the culture medium
(63–69 kDa), using a murine anti-human GCR polyclonal
antibody [34]. GCR has a molecular mass ranging from
59 to 69 kDa [36], depending on the complexity of its
glycan chains [1, 51], while the nonglycosylated GCR is a
nonfunctional enzyme of 56 kDa [39]. Thus, the molecular
masses detected here for recombinant human GCR are
consistent with a properly glycosylated and active enzyme.
However, to use in ERT, GCR should be modified in the
oligosaccharide moieties to produce mannose-terminal car-
bohydrates, facilitating mannose receptor-mediated uptake
into macrophages [52]. GCR produced in CHO cells and
commercialized by Genzyme is sequentially treated with
three exoglycosidases during purification process to remove
sialic acid, galactose, and N-acetylglucosamine residues [53,
54]. These steps have to be further included in our future
production process of a therapeutically functional enzyme in
CHO cells in order to obtain a biosimilar GCR.
To evaluate the stability of the producer clone, MTX was
withdrawn from the culture medium and an unexpected
decreased in the GCR expression was observed. Long-
term culture in the absence of selective pressure may
result in the loss of transgene copy number [55, 56], and
reduction or elimination in the gene-specific transcription
(gene silencing) [49, 57], according to the site of transgene
integration. Both processes may result in the prevalence of
cells expressing lower levels of the recombinant protein due
to the higher growth rate presented by these cells when
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Figure 6: Glycosylation analysis of recombinant GCR secreted from high-producer subclone (SC 12.9) by western blotting assays. (a)
Endoglycosidase digestion with Endo H and PNGase F. Samples of conditioned medium (supernatant of 150,000 cells corresponding to
about 750 ng of GCR) were precipitated with 10% TCA previously to digestion reactions. Non-digested sample of nontransfected CHO-
DXB11 cells was used as negative control. Nonglycosylated recombinant GCR purified from E. coli was a positive control. Glycosylated GCR
bands of 66–69 kDa and nonglycosylated GCR of 56 kDa are indicated by solid and dashed arrows, respectively. (b) Purified commercial
enzyme Cerezyme (150 ng) of 60 kDa containing remodeled glycosylation moieties was compared to GCR secreted from subclone 12.9
(supernatant of 30,000 cells corresponding to about 150 ng) with complex- and hybrid-type glycosylation pattern (66–69 kDa).
compared with the high producers [58], despite the fact that
both have potentially been derived from the same single cell
[56, 57].
Recloning was then performed in order to evaluate the
heterogeneity of the producer clone, and stable subclones
expressing a functional GCR with level of biological activity
similar to that of Cerezyme were identified. Although
the highest productivity achieved for secreted GCR was
calculated as 5.14 pg/cell/day, higher expression levels have
been reported for other recombinant proteins in CHO cells
[45, 47]. Here, it should be taken into account the fact
that GCR is a membrane-associated glycoprotein secreted
at low level or rather not secreted under natural conditions
[37]. Despite the importance of the production of GCR
for the treatment of ERT, there is a lack of data in the
literature describing the expression of recombinant GCR
in CHO cells. Leonova and Grabowski [37] reported the
intracellular degradation and secretion processes of GCR in
stably transfected CHO cells, and Genzyme’s data concerning
the production of imiglucerase in CHO-DG44 cells were
only summarily described by Hoppe [59]. Additionally, some
other information can be found in the patent files [44, 53].
Here, we report a robust protocol for the production of
recombinant GCR in CHO cells along with the all the steps
to obtain a stable cell line expressing the enzyme.
In conclusion, we showed the generation of stable CHO
cells producing a functional recombinant human GCR,
properly glycosylated and secreted, using low-throughput
methods for selection of high-producing clones. Eﬀorts
to develop a process for producing GCR by nonprofit
institution may possibly result in reduced cost of treating
Gaucher disease in the future thus supplying the needs of
the Brazilian public healthcare system. Furthermore, the
traditional screening strategies shown here can be useful
for other emerging countries to produce biopharmaceuticals
and other biological products of high cost-eﬀectiveness and
public health value.
Acknowledgments
The authors are grateful to Dr. Geraldo Santana Magalha˜es
(Laborato´rio de Imunopatologia, Instituto Butantan) and
Dr. Eneas de Carvalho (Centro de Biotecnologia, Instituto
Butantan) for helpful discussions, to Dr. Rosa Maria Chura-
Chambi (Centro de Biotecnologia, Instituto de Pesquisas
Energe´ticas e Nucleares) for helping them with the transfec-
tion and gene amplification procedures, and to Dr. Henrique
Roman Ramos (Centro de Biotecnologia, Instituto Butan-
tan) for assistance in the fluorometric analysis. This work was
supported by grants from FAPESP (Fundac¸a˜o de Amparo
a` Pesquisa do Estado de Sa˜o Paulo), CNPq (Conselho
Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico), and
Fundac¸a˜o Butantan.
References
[1] A. H. Erickson, E. I. Ginns, and J. A. Barranger, “Biosynthesis
of the lysosomal enzyme glucocerebrosidase,” The Journal of
Biological Chemistry, vol. 260, no. 26, pp. 14319–14324, 1985.
[2] E. Beutler, “Gaucher disease: new molecular approaches to
diagnosis and treatment,” Science, vol. 256, no. 5058, pp. 794–
799, 1992.
Journal of Biomedicine and Biotechnology 9
[3] R. O. Brady, J. N. Kanfer, and D. Shapiro, “Metabolism of
glucocerebrosides II. Evidence of an enzymatic deficiency
in Gaucher’s disease,” Biochemical and Biophysical Research
Communications, vol. 18, no. 2, pp. 221–225, 1965.
[4] M. Jmoudiak and A. H. Futerman, “Gaucher disease: patho-
logical mechanisms andmodernmanagement,” British Journal
of Haematology, vol. 129, no. 2, pp. 178–188, 2005.
[5] D. Elstein and A. Zimran, “Review of the safety and eﬃcacy of
imiglucerase treatment of Gaucher disease,” Biologics, vol. 3,
pp. 407–417, 2009.
[6] G. A. Grabowski, “Recent clinical progress in Gaucher dis-
ease,”Current Opinion in Pediatrics, vol. 17, no. 4, pp. 519–524,
2005.
[7] J. A. Barranger and E. O’Rourke, “Lessons learned from the
development of enzyme therapy for Gaucher disease,” Journal
of Inherited Metabolic Disease, vol. 24, no. 2, supplement, pp.
89–96, 2001.
[8] G. A. Grabowski, “Phenotype, diagnosis, and treatment of
Gaucher’s disease,” The Lancet, vol. 372, no. 9645, pp. 1263–
1271, 2008.
[9] E. Beutler, “Enzyme replacement in Gaucher disease,” PLoS
Medicine, vol. 1, article e21, pp. 118–121, 2004.
[10] R. O. Brady, P. G. Pentchev, and A. E. Gal, “Replacement
therapy for inherited enzyme deficiency. Use of purified
glucocerebrosidase in Gaucher’s disease,” The New England
Journal of Medicine, vol. 291, no. 19, pp. 989–993, 1974.
[11] Y. Kacher, B. Brumshtein, S. Boldin-Adamsky et al., “Acid β-
glucosidase: onsights from structural analysis and relevance to
Gaucher disease therapy,” Biological Chemistry, vol. 389, no.
11, pp. 1361–1369, 2008.
[12] K. Starzyk, S. Richards, J. Yee, S. E. Smith, and W. Kingma,
“The long-term international safety experience of imiglu-
cerase therapy for Gaucher disease,” Molecular Genetics and
Metabolism, vol. 90, no. 2, pp. 157–163, 2007.
[13] P. B. Deegan and T. M. Cox, “Imiglucerase in the treatment
of Gaucher disease: a history and perspective,” Drug Design,
Development and Therapy, vol. 6, pp. 81–106, 2012.
[14] T. M. Cox, “Gaucher disease: clinical profile and therapeutic
developments,” Biologics, vol. 4, pp. 299–313, 2011.
[15] J. M. F. G. Aerts, U. Yasothan, and P. Kirkpatrick, “Velaglu-
cerase alfa,” Nature Reviews Drug Discovery, vol. 9, no. 11, pp.
837–838, 2010.
[16] K. Traynor, “Taliglucerase alfa approved for Gaucher disease,”
American Journal of Health-System Pharmacy, vol. 69, no. 12,
p. 1009, 2012.
[17] B. Brumshtein, P. Salinas, B. Peterson et al., “Characterization
of gene-activated human acid-β-glucosidase: crystal structure,
glycan composition, and internalization into macrophages,”
Glycobiology, vol. 20, no. 1, pp. 24–32, 2010.
[18] J. L. Morris, “Velaglucerase alfa for the management of type 1
Gaucher disease,” Clinical Therapeutics, vol. 34, pp. 259–271,
2012.
[19] A. Zimran, K. Loveday, C. Fratazzi, and D. Elstein, “A phar-
macokinetic analysis of a novel enzyme replacement therapy
with Gene-Activated human glucocerebrosidase (GA-GCB) in
patients with type 1 Gaucher disease,” Blood Cells, Molecules,
and Diseases, vol. 39, no. 1, pp. 115–118, 2007.
[20] C. E. Hollak, “An evidence-based review of the potential
benefits of taliglucerase alfa in the treatment of patients with
Gaucher disease,” Core Evidence, vol. 7, pp. 15–20, 2012.
[21] Y. Shaaltiel, D. Bartfeld, S. Hashmueli et al., “Production of
glucocerebrosidase with terminal mannose glycans for enzyme
replacement therapy of Gaucher’s disease using a plant cell
system,” Plant Biotechnology Journal, vol. 5, no. 5, pp. 579–590,
2007.
[22] C. E. M. Hollak, S. vom Dahl, J. M. F. G. Aerts et al.,
“ForceMajeure: therapeutic measures in response to restricted
supply of imiglucerase (Cerezyme) for patients with Gaucher
disease,” Blood Cells, Molecules, and Diseases, vol. 44, no. 1, pp.
41–47, 2010.
[23] E. Beutler, “Gaucher disease as a paradigm of current issues
regarding single gene mutations of humans,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 90, no. 12, pp. 5384–5390, 1993.
[24] E. Beutler, “Lysosomal storage diseases: natural history and
ethical and economic aspects,” Molecular Genetics and Metab-
olism, vol. 88, no. 3, pp. 208–215, 2006.
[25] A. H. Futerman, J. L. Sussman, M. Horowitz, I. Silman, and A.
Zimran, “New directions in the treatment of Gaucher disease,”
Trends in Pharmacological Sciences, vol. 25, no. 3, pp. 147–151,
2004.
[26] R. J. Kaufman, M. V. Davies, L. C. Wasley, and D. Michnick,
“Improved vectors for stable expression of foreign genes in
mammalian cells by use of the untranslated leader sequence
from EMC virus,” Nucleic Acids Research, vol. 19, no. 16, pp.
4485–4490, 1991.
[27] G. Urlaub and L. A. Chasin, “Isolation of Chinese hamster
cell mutants deficient in dihydrofolate reductase activity,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 77, no. 7, pp. 4216–4220, 1980.
[28] J. J. Cacciatore, L. A. Chasin, and E. F. Leonard, “Gene amplifi-
cation and vector engineering to achieve rapid and high-level
therapeutic protein production using the Dhfr-based CHO
cell selection system,” Biotechnology Advances, vol. 28, no. 6,
pp. 673–681, 2010.
[29] R. J. Kaufman, “Selection and coamplification of heterologous
genes in mammalian cells,” Methods in Enzymology, vol. 185,
pp. 537–566, 1990.
[30] K. P. Jayapal, K. F. Wlaschin, W. S. Hu, and M. G. S.
Yap, “Recombinant protein therapeutics from CHO Cells—20
years and counting,” Chemical Engineering Progress, vol. 103,
no. 10, pp. 40–47, 2007.
[31] F.M.Wurm, “Production of recombinant protein therapeutics
in cultivated mammalian cells,” Nature Biotechnology, vol. 22,
no. 11, pp. 1393–1398, 2004.
[32] F. Sanger, S. Nicklen, and A. R. Coulson, “DNA sequencing
with chain-terminating inhibitors,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 74, no.
12, pp. 5463–5467, 1977.
[33] F. L. Graham and A. J. van der Eb, “A new technique for the
assay of infectivity of human adenovirus 5 DNA,”Virology, vol.
52, no. 2, pp. 456–467, 1973.
[34] J. B. Novo, M. L. S. Oliveira, G. S. Magalha˜es, L. Morganti,
I. Raw, and P. L. Ho, “Generation of polyclonal antibodies
against recombinant human glucocerebrosidase produced in
escherichia coli,” Molecular Biotechnology, vol. 46, no. 3, pp.
279–286, 2010.
[35] C. M. Stoscheck, “Quantitation of protein,” Methods in Enzy-
mology, vol. 182, pp. 50–68, 1990.
[36] J. E. Bergmann and G. A. Grabowski, “Posttranslational pro-
cessing of human lysosomal acid β-glucosidase: a continuum
of defects in Gaucher disease type 1 and type 2 fibroblasts,”
American Journal of Human Genetics, vol. 44, no. 5, pp. 741–
750, 1989.
10 Journal of Biomedicine and Biotechnology
[37] T. Leonova and G. A. Grabowski, “Fate and sorting of acid
β-glucosidase in transgenic mammalian cells,” Molecular
Genetics and Metabolism, vol. 70, no. 4, pp. 281–294, 2000.
[38] M. Beck, “Therapy for lysosomal storage disorders,” IUBMB
Life, vol. 62, no. 1, pp. 33–40, 2010.
[39] A. Berg-Fussman, M. E. Grace, Y. Ioannou, and G. A.
Grabowski, “Human acid β-glucosidase. N-glycosylation site
occupancy and the eﬀect of glycosylation on enzymatic
activity,” The Journal of Biological Chemistry, vol. 268, no. 20,
pp. 14861–14866, 1993.
[40] M. E. Grace and G. A. Grabowski, “Human acid β-glucosidase:
glycosylation is required for catalytic activity,” Biochemical and
Biophysical Research Communications, vol. 168, no. 2, pp. 771–
777, 1990.
[41] S. A. Brooks, “Appropriate glycosylation of recombinant
proteins for human use: implications of choice of expression
system,” Applied Biochemistry and Biotechnology—Part B, vol.
28, no. 3, pp. 241–256, 2004.
[42] Y. Durocher and M. Butler, “Expression systems for therapeu-
tic glycoprotein production,” Current Opinion in Biotechnol-
ogy, vol. 20, no. 6, pp. 700–707, 2009.
[43] G. Walsh, “Post-translational modifications of protein bio-
pharmaceuticals,”Drug Discovery Today, vol. 15, no. 17-18, pp.
773–780, 2010.
[44] J. Rasmussen, G. Barsomian, and M. Bergh, “Enzymatically
active recombinant glucocerebrosidase,” US Patent, 5, 236,
838, 1993.
[45] R. M. Chura-Chambi, P. H. Tornieri, P. J. Spencer, P. A. Nasci-
mento, M. B. Mathor, and L. Morganti, “High-level synthesis
of recombinant murine endostatin in Chinese hamster ovary
cells,” Protein Expression and Purification, vol. 35, no. 1, pp.
11–16, 2004.
[46] C. N. Peroni, C. R. J. Soares, E. Gimbo, L. Morganti, M. T. C.
P. Ribela, and P. Bartolini, “High-level expression of human
thyroid-stimulating hormone in Chinese hamster ovary cells
by co-transfection of dicistronic expression vectors followed
by a dual-marker amplification strategy,” Biotechnology and
Applied Biochemistry, vol. 35, no. 1, pp. 19–26, 2002.
[47] C. R. J. Soares, L. Morganti, B. Miloux, J. H. Lupker, P. Ferrara,
and P. Bartolini, “High-level synthesis of human prolactin
in Chinese-hamster ovary cells,” Biotechnology and Applied
Biochemistry, vol. 32, no. 2, pp. 127–135, 2000.
[48] D. Kuystermans, B. Krampe, H. Swiderek, and M. Al-Rubeai,
“Using cell engineering and omic tools for the improvement
of cell culture processes,” Cytotechnology, vol. 53, no. 1–3, pp.
3–22, 2007.
[49] D. L. Hacker, M. De Jesus, and F. M. Wurm, “25 years of
recombinant proteins from reactor-grown cells—where do we
go from here?” Biotechnology Advances, vol. 27, no. 6, pp.
1023–1027, 2009.
[50] S. M. Browne andM. Al-Rubeai, “Selection methods for high-
producing mammalian cell lines,” Trends in Biotechnology, vol.
25, no. 9, pp. 425–432, 2007.
[51] S. Takasaki, G. J. Murray, and F. S. Furbish, “Structure of the
N-asparagine-linked oligosaccharide units of human placental
β-glucocerebrosidase,” The Journal of Biological Chemistry, vol.
259, no. 16, pp. 10112–10117, 1984.
[52] S. M. Van Patten, H. Hughes, M. R. Huﬀ et al., “Eﬀect of
mannose chain length on targeting of glucocerebrosidase for
enzyme replacement therapy of Gaucher disease,” Glycobiol-
ogy, vol. 17, no. 5, pp. 467–478, 2007.
[53] B. Friedman and M. Hayes, “Enhanced in vivo uptake of
glucocerebrosidase,” US Patent, 5, 549, 892, 1996.
[54] F. S. Furbish, C. J. Steer, N. L. Krett, and J. A. Barranger,
“Uptake and distribution of placental glucocerebrosidase in
rat hepatic cells and eﬀects of sequential deglycosylation,”
Biochimica et Biophysica Acta, vol. 673, no. 4, pp. 425–434,
1981.
[55] C. H. Fann, F. Guirgis, G. Chen, M. S. Lao, and J. M. Piret,
“Limitations to the amplification and stability of human
tissue-type plasminogen activator expression by Chinese ham-
ster ovary cells,” Biotechnology and Bioengineering, vol. 69, no.
2, pp. 204–212, 2000.
[56] N. S. Kim, S. J. Kim, and G. M. Lee, “Clonal variability within
dihydrofolate reductase-mediated gene amplified Chinese
hamster ovary cells: stability in the absence of selective pres-
sure,” Biotechnology and Bioengineering, vol. 60, pp. 679–688,
1998.
[57] J. Chusainow, Y. S. Yang, J. H. M. Yeo et al., “A study of
monoclonal antibody-producing CHO cell lines: what makes
a stable high producer?” Biotechnology and Bioengineering, vol.
102, no. 4, pp. 1182–1196, 2009.
[58] M. B. Gu, J. A. Kern, P. Todd, and D. S. Kompala, “Eﬀect of
amplification of dhfr and lac Z genes on growth and β-gal-
actosidase expression in suspension cultures of recombinant
CHO cells,” Cytotechnology, vol. 9, no. 1–3, pp. 237–245, 1992.
[59] H. Hoppe, “Cerezyme—recombinant protein treatment for
Gaucher’s disease,” Journal of Biotechnology, vol. 76, no. 2-3,
pp. 259–261, 2000.
